Extracorporeal membrane oxygenation with danaparold sodium after massive pulmonary embolism

被引：18

作者：

Bauer, Christian ^{[1
,2
]}

Vichova, Zuzana ^{[1
,2
]}

Ffrench, Patrick ^{[2
,4
]}

Hercule, Christiane ^{[2
]}

Jegaden, Olivier ^{[2
,3
]}

Bastien, Olivier ^{[1
,2
]}

Lehot, Jean-Jacques ^{[1
,2
]}

机构：

[1] Hop Cardiovasc & Pneumol Louis Pradel, Anesthesiol & Intens Care Unit, Hosp Civil Lyon, F-69677 Bron, France

[2] Univ Lyon 1, F-69622 Villeurbanne, France

[3] Hop Cardiovasc & Pneumol Louis Pradel, Dept Cardiovasc Surg, Hosp Civil Lyon, F-69677 Bron, France

[4] Hop Cardiovasc & Pneumol Louis Pradel, Hemostasis Lab, Hosp Civil Lyon, F-69677 Bron, France

来源：

ANESTHESIA AND ANALGESIA | 2008年 / 106卷 / 04期

关键词：

D O I：

10.1213/ane.0b013e31816794d9

中图分类号：

R614 [麻醉学];

学科分类号：

100217 ;

摘要：

During extracorporeal membrane oxygenation, anticoagulation therapy is usually achieved with unfractionated heparin. We report on an extracorporeal membrane oxygenation with danaparoid sodium for a patient with severe respiratory failure due to massive pulmonary embolism and suspected type 2 heparin-induced thrombocytopenia. Danaparoid, a low molecular weight heparinoid, is an alternative to heparin for patients who develop type 2 heparin-induced thrombocytopenia. Danaparoid was given at 400 IU/h with an objective of antifactor Xa activity of 0.6-0.8 U/mL, which was monitored twice a day. No excessive bleeding or clotting of the circuit was noted. The patient was weaned from extracorporeal membrane oxygenation after 9 days of treatment.

引用

页码：1101 / 1103

页数：3

共 29 条

[1] Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia [J].

Aouifi, A ;

Blanc, P ;

Piriou, V ;

Bastien, OH ;

Ffrench, P ;

Hanss, M ;

Lehot, JJ .

ANNALS OF THORACIC SURGERY, 2001, 71 (02) :678-683

[2] Failure of danaparoid anticoagulation for cardiopulmonary bypass [J].

Ariano, RE ;

Bhattacharya, SK ;

Moon, M ;

Brownell, LG .

JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2000, 119 (01) :167-168

[3] The mechanisms of platelet dysfunction during extracorporeal membrane oxygenation in critically ill neonates [J].

Cheung, PY ;

Sawicki, G ;

Salas, E ;

Etches, PC ;

Schulz, R ;

Radomski, MW .

CRITICAL CARE MEDICINE, 2000, 28 (07) :2584-2590

[4]

Christiansen, 1998, Int J Angiol, V7, P268, DOI 10.1007/BF01617410

[5] Extracorporeal membrane oxygenation for the treatment of massive pulmonary embolism [J].

Davies, MJ ;

Arsiwala, SS ;

Moore, HM ;

Kerr, S ;

Sosnowski, AW ;

Firmin, RK .

ANNALS OF THORACIC SURGERY, 1995, 60 (06) :1801-1803

[6] HEPARIN-FREE CARDIOPULMONARY BYPASS - 1ST REPORTED USE OF HEPARINOID (ORG 10172) TO PROVIDE ANTICOAGULATION FOR CARDIOPULMONARY BYPASS [J].

DOHERTY, DC ;

ORTEL, TL ;

DEBRUIJN, N ;

GREENBERG, CS ;

VANTRIGT, P .

ANESTHESIOLOGY, 1990, 73 (03) :562-565

[7] Travel as a risk factor for venous thromboembolic disease - A case-control study [J].

Ferrari, E ;

Chevallier, T ;

Chapelier, A ;

Baudouy, M .

CHEST, 1999, 115 (02) :440-444

[8] Danaparoid for cardiopulmonary bypass in patients with previous heparin-induced thrombocytopenia [J].

Gillis, S ;

Merin, G ;

Zahger, D ;

Deeb, M ;

Drenger, B ;

Hyam, E ;

Eldor, A .

BRITISH JOURNAL OF HAEMATOLOGY, 1997, 98 (03) :657-659

[9] Intraoperative monitoring of danaparoid sodium anticoagulation during cardiovascular operations [J].

Gitlin, SD ;

Deeb, GM ;

Yann, C ;

Schmaier, AH .

JOURNAL OF VASCULAR SURGERY, 1998, 27 (03) :568-575

[10] Coagulation complicating cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia receiving the heparinoid, danaparoid sodium [J].

Grocott, HP ;

Root, J ;

Berkowitz, SD ;

deBruijn, N ;

Landolfo, K .

JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 1997, 11 (07) :875-877

← 1 2 3 →